Silver Oxysalts offer a new option in the fight against deadly infections in Chronic Wounds


DOYLESTOWN, Pa., April XX, 2017 – Crawford Healthcare, Inc. (“Crawford” or the “Company”) recently supported a panel of speakers at the Symposium for Advanced Wound Care (SAWC) in San Diego, CA. The panel, composed of internationally recognized clinicians and scientists, shared their clinical and in vitro experience in utilizing the patented silver compound, Ag Oxysalts™ Technology, in the fight against wound infections and biofilms.

The symposium was moderated by Dr. Marco Romanelli, a world-renowned wound physician and an Assistant Professor at the University of Pisa in Italy. The panel also included Lindsay Kalan PhD, from the University of Pennsylvania Department of Dermatology, Catherine Milne from Connecticut Clinical Nursing Associates and Dr. Charles Lee, FACS who is the Chief of Plastic Surgery at St. Mary’s Medical Center in San Francisco.

Ag Oxysalts was recently combined into a new dressing and cleared by the FDA. This dressing, named KerraCel® Ag, combines Carboxymethyl Cellulose (CMC) to handle excess exudate with Ag Oxysalts™ to manage infection and break through biofilm. The Ag Oxysalts™ Technology, licensed through Exciton Technologies, has a unique mode of action which makes it significantly more reactive when in contact with wound fluid and up to six times more powerful than traditional silver compounds. The increased reactivity leads to a quick 99.999% kill of bacteria – including superbugs – and the ability to break through biofilm to kill the bacteria within.

For more information about Crawford Healthcare, Inc. or its products, please visit


About Crawford Healthcare, Inc.

Crawford Healthcare, Inc., is a rapidly growing international company dedicated to developing innovative treatments and effective dermatological, wound care, and diagnostic products for the care and repair of skin. The Company has worked closely with healthcare professionals for more than 15 years from the international head office of its parent company, Crawford Healthcare Holdings Limited (the “Crawford Group”), in Knutsford, Cheshire, U.K. In early 2013, the Crawford Group expanded its operations and opened a United States office in Doylestown, Pa., that focuses on the Company’s portfolio of advanced wound care products. To help lead its U.S. business, the Crawford Group has assembled a skilled management team with long-standing industry backgrounds in the advanced wound care arena. The team offers more than 150 years of collective experience in the field and has deployed a nationwide direct sales team dedicated to wound, skin, and burn care.

About Exciton Technologies, Inc.
Exciton Technologies Inc. (inc. 2001) is a Canadian advanced materials research and development company that focuses on the creation of technologies for preventing and controlling infection. Exciton’s technologies are capable of bringing silver-based wound care products out of the elite market segment and into broader commercial and consumer applications. Advantages include an advanced higher valence ionic silver state designed to be a broad spectrum antimicrobial barrier.